神经元活动与β淀粉样蛋白在阿尔茨海默病内嗅皮层tau蛋白播散中的作用

The entorhinal cortex is the first region to develop tau pathology in Alzheimer's disease and primary age-related tauopathy, yet the reasons for this selective vulnerability remain unclear. We developed a computational model in which neuronal activity and amyloid-β (Aβ) modulate tau transport, hypothesizing that this mechanism explains entorhinal vulnerability to early tau pathology. The model combines structural connectivity with either neuronal activity (measured by FDG PET) or Aβ burden (measured by Aβ PET). We analysed Alzheimer's Disease Neuroimaging Initiative (ADNI) data comprising 527 FDG PET scans (mean age 71.8 years; 174 cognitively normal, 293 mild cognitive impairment, 60 Alzheimer's disease) and 1244 Aβ PET scans (mean age 72.4 years; 501 cognitively normal, 588 mild cognitive impairment, 155 Alzheimer's disease). From these, 253 FDG-tau and 453 Aβ-tau PET pairs were used in regression analyses. Key results were replicated in the Harvard Aging Brain Study (HABS; 300 FDG, 348 Aβ, 116 FDG-tau and 255 Aβ-tau pairs). Both FDG- and Aβ-based models consistently identified the entorhinal cortex as a primary tau seeding region in ADNI (FDG: z ≈ 4.6-4.9, P < 0.0066; Aβ: z ≈ 4.0-8.7, P ≤ 0.011) and in HABS (FDG: z = 5.7, P = 0.030; Aβ: z = 6.0, P = 0.0018). Simple linear regression showed modest associations between model-derived seeding and empirical entorhinal tau in ADNI (FDG: β = 6.7, P = 0.0039; Aβ: β = 11.3, P < 0.001), which remained significant after adjustment for age, sex, and APOE4 status (FDG: β = 7.1, P < 0.001; Aβ: β = 9.7, P < 0.001). Aβ-based associations replicated in HABS (β = 3.3, P < 0.001), while FDG-based correlations were not detectable in this predominantly cognitively normal cohort (β = -0.43, P = 0.80; power = 49%). These findings support a mechanistic role for neuronal activity and Aβ in initiating tau pathology, with the entorhinal cortex consistently emerging as highly vulnerable. Our computational model reliably identifies this region as the epicentre of pathology, supporting the idea that brain-wide patterns of neuronal activity and amyloid burden determine where tau pathology begins.